Prolonged administration of oral etoposide alone or with intravenous carboplatin in stage IV non-small cell lung cancer: A randomized trial

Lung Cancer

Volumn 18, Issue 2, 1997, Pages 179-188

  Jeremic, Branislav ^a   Shibamoto, Yuta ^b   Acimovic, Ljubisa ^c   Milicic, Biljana ^a   Milisavljevic, Slobodan ^c   Nikolic, Nebojsa ^a  

^a KBC Kragujevac ^*  (Serbia)

^b KYOTO UNIVERSITY   (Japan)

^c University Hospital   (Serbia)

Author keywords

Carboplatin; Etoposide; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; ETOPOSIDE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0030928078     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00063-9     Document Type: Article

References (29)

1. Abratt RP, Bezwoda WR, Goedhals L, et al. Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer. J Clin Oncol 1997;15:744-99.
2. Blumenreich MS, Sheth SP, Miller CL, et al. Inefficacy of low-dose continuous oral etoposide in non-small cell lung cancer. Am J Clin Oncol (CCT) 1994;17:163-5.
3. Bonomi P, Finkelstein DM, Ruckdeschel JC, et al. Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern cooperative oncology Group. J Clin Oncol 1989;7:1602-13.
4. Bonomi P, Kim K, Chang A, et al. Phase III trial comparing etoposide (E) cisplatin (C) versus taxol (T) with cisplatin-G-CSF (G) versus taxol-cisplatin in advanced non-small cell lung cancer. An Eastern cooperative oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 1996:382.
5. Cullen MH. Trials with mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer. Lung Cancer 1995;12(Suppl. 1):S95-S106.
6. Depierre A, Chastang CI, Quix E, et al. Vinorelbine versus vinorelbine plus cisplatin in advanced non-small-cell lung cancer: A randomized trial. Ann Oncol 1994;5:37-42.
7. Frasci G, Perrilo G, Comelia P, et al. Phase I/II study of carboplatin and oral etoposide with granulocyte-colony stimulating factor in advanced non-small cell lung cancer. Cancer 1995;75:1578-85.
8. Giaccone G, Splinter T, Postmus P, et al. Paclitaxel-cisplatin versus teniposide-cisplatin in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1996:373.
9. Gridelli C, Perrone F, Palmeri S, et al. Mitomycin C plus vindesine plus etoposide (MEV) versus mitomycin C plus vindesine plus cisplatin (MVP) in stage IV non-small-cell lung cancer: A phase III multicentre randomized trial. Ann Oncol 1996;7:821-6.
10. Hainsworth JD, Johnson DH, Frazier SR, et al. Chronic daily administration of oral etoposide: A phase I trial. J Clin Oncol 1989;7:396-401.
11. Hainsworth JD, Thompson DS, Urba WJ, et al. One hour paclitaxel plus carboplatin in advanced non-small cell lung cancer (NSCLC): Preliminary results of a multi-institutional phase II study. Proc Am Soc Clin Oncol 1996:379.
12. Hirabayashi M, Tanaka Y, Hitoshi Y, et al. Treatment of unresectable non-small cell lung cancer (NSCLC) with carboplatin and chronic daily administration of oral etoposide. Jpn J Cancer Chemother 1994;21:53-8.
13. Jeremic B, Acimovic Lj, Mijatovic Lj. Carboplatin and etoposide in advanced colorectal carcinoma: a phase II study.. Cancer 1993;71:2706-8.
14. Jeremic B, Grujicic D, Jevremovic S, et al. Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: a phase II study. J Clin Oncol 1992;10:1074-7.
15. Johnson DH, Hainsworth JD, DeVore R, et al. Carboplatin plus oral etoposide in the management of unresectable non-small cell lung cancer: preliminary results of a Vanderbilt Trial. Oncology 1992;49(Suppl. 1):57-62.
16. Johnson DH, Paul DM, Hande KR, et al. Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 1996;14:2054-60.
17. Kunitoh H, Watanabe K, Onoshi T, et al. Phase II trial of docetaxel in previously untreated non-small-cell lung cancer: A Japanese Cooperative study. J Clin Oncol 1996;14:1649-55.
18. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer (NSCLC): A phase II toxicity, response, and survival analysis (FCCC 93-024). J Clin Oncol 1995;13:1860-70.
19. LeChevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 1994;12:360-7.
20. Marino P, Preatoni A, Cantoni G, et al. Single-agent chemotherapy versus combination chemotherapy in advanced non-small cell lung cancer: a quality and meta-analysis study. Lung Cancer 1995;13:1-12.
21. Miller AA, Tolley EA, Niell HB, et al. Pharmacodynamics of prolonged oral etoposide in patients with advaced non-small cell lung cancer. J Clin Oncol 1993;11:1179-88.
22. Non Small Cell Lung Cancer Cooperative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995;311:899-909.
23. Pedersen AG, Hansen HH. Etoposide (VP 16) in the treatment of lung cancer. Cancer Treat Rev 1983;10:245-64.
24. Saxman S, Logie K, Stephens D, et al. Phase II trial of daily oral etoposide in patients with surgically unresectasble non-small cell lung cancer. Invest New Drugs 1991;9:253-6.
25. Slevin ML, Staquet MJ. Randomized trials in cancer. A critical review by sites. In: Monograph series of the Europen Organization for Research and Treatment of Cancer. Vol. 15. New York: Raven Press, 1986:342-344.
26. Slevin MI, Clark PI, Malik S, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989;7:1333-4.
27. Souqet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: A meta analysis. Lancet 1993;342:19-21.
28. Splinter TAW. Chemotherapy in advanced non-small cell lung cancer. Eur J Cancer 1990;26:1093-9.
29. Waits TM, Johnson DH, Hainsworth JD, et al. Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial. J Clin Oncol 1992;10:292-6.